A Phase II, Multi-center, Randomized and Open Study to Evaluate and Compare the PK, PD and Safety of SCT400 With Rituximab in Patients With CD20+ B-cell Non-Hodgkin's Lymphoma

Trial Profile

A Phase II, Multi-center, Randomized and Open Study to Evaluate and Compare the PK, PD and Safety of SCT400 With Rituximab in Patients With CD20+ B-cell Non-Hodgkin's Lymphoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Feb 2017

At a glance

  • Drugs SCT 400 (Primary) ; Rituximab
  • Indications B cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Pharmacokinetics
  • Sponsors Sinocelltech
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 03 Jun 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top